mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

BACKGROUND: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patient...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bogani, Costanza, Bartalucci, Niccolò, Martinelli, Serena, Tozzi, Lorenzo, Guglielmelli, Paola, Bosi, Alberto, Vannucchi, Alessandro M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3561413/
https://ncbi.nlm.nih.gov/pubmed/23382981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0054826
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak